ClinicalTrials.gg
Not yet recruitingNCT07649512Updated Nov 12, 2026

Progressive Muscle Relaxation Delivered Via Virtual Reality - an Intervention for Patients Undergoing Cellular Therapy

An interventional study of Progressive Muscle Relaxation delivered via Virtual Reality in Heme Malignancy, sponsored by University of Arizona. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Arizona · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients planned for cellular therapy supplementation such as CAR-T or stem cell transplant who are admitted for atleast 7 days in patient. During that time of admission, patients enrolled will complete a once daily, virtual reality guided progressive muscle relaxation program. Various validated QOL tools will be utilized to assess study results.

02

Conditions studied

  • Heme Malignancy
03

In context

Lead sponsor

University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide
  2. Age greater than or equal to 18 years old
  3. Either have a planned admission or already be admitted to the in-patient oncology ward (3NW) with cellular therapy needs.
  4. Able to understand English
  5. Able to sit-up in bed or bedside chair space to utilize VR device at the time of enrollment
  6. Able to utilize VR device and computer/laptop to access necessary resources for participation
  7. Performance Status as defined by European Cooperative Oncology Group () score of 0-2

Exclusion criteria

Exclusion Criteria:

  1. Poor performance status of 3-4
  2. Recent use of immersive VR programs for stress relief and/or entertainment (more than 2 days/week within the past 3 months)
  3. Participation in another stress-reduction type interventional study within the past 3 months
  4. Current or history of seizure, epilepsy, or other known severe neurological or mental health disorders
  5. Clinical Sensitivity to flashing light or motion or having balance disorders previously diagnosed
  6. Having another medical condition or co-morbidity that may prevent use of VR program or physical materials (e.g., visual or hearing problems, open sores, wounds, skin rash on face, or active infection)
  7. Patients with concern for neurotoxicity or acute treatment related neurological issues such as ICANS. ICANS grade 1 maybe eligible to re-enter trial. ICANS grade 2 or greater would be permanently excluded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention arm - single arm feasibility study

    Patients will undergo intervention (PMR delivered via VR). All patients will undergo the intervention.

    Combination Product: Progressive Muscle Relaxation delivered via Virtual Reality

Interventions

  • Combination productProgressive Muscle Relaxation delivered via Virtual Reality

    Patients will utilize VR headset in the intervention arm. This headset will be pre-populated with PMR guided meditation videos.

06

What researchers measure

Primary outcomes

  1. Recruitment, Retention, and Adherence Rates of VR-Guided Progressive Muscle Relaxation (PMR) Intervention

    Feasibility will be assessed using three operational metrics: Recruitment rate - the proportion of eligible patients who consent to participate in the study. Retention rate - the proportion of enrolled participants who complete the 7-day intervention period. Adherence rate - the proportion of participants who complete at least 5 VR-guided PMR sessions lasting up to 20 minutes each during the first 7 days of hospitalization. These outcomes will be summarized descriptively as proportions and percentages among enrolled participants.

    Time frame: Enrollment through completion of the 7-day intervention period.

Secondary outcomes

  1. Change in Symptom Scores Using the Edmonton Symptom Assessment System-Revised (ESAS-r)

    The Edmonton Symptom Assessment System-Revised (ESAS-r) is a validated patient-reported symptom assessment tool used to measure common physical and psychological symptoms in patients with cancer. The ESAS-r assesses nine symptoms (pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath) using a numeric rating scale from 0 to 10 for each symptom, where 0 indicates no symptom and 10 indicates the worst possible symptom severity. Changes in individual symptom scores and total symptom burden will be summarized descriptively from baseline to Day 7 following the intervention.

    Time frame: Baseline (Day 1) through Day 7 following enrollment.

  2. Change in Health-Related Quality of Life Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) is a validated patient-reported instrument used to assess health-related quality of life in patients with cancer. The questionnaire contains 30 items assessing global health status, functional domains (physical, role, cognitive, emotional, and social functioning), and symptom domains. Scores are transformed to a 0-100 scale according to the EORTC scoring manual. For the global health status and functional scales, higher scores indicate better quality of life and functioning, whereas for the symptom scales, higher scores indicate greater symptom burden. Changes in global health status and symptom scores from baseline to Day 7 will be summarized descriptively.

    Time frame: Baseline (Day 1) through Day 7 following enrollment.

  3. Change in Muscle Relaxation Intensity Using a Visual Analog Scale (VAS)

    Perceived muscle tension and relaxation will be assessed using a Visual Analog Scale (VAS). Participants will rate their perceived level of muscle tension and relaxation on a numeric scale from 0 to 10, where 0 represents no tension/complete relaxation and 10 represents the highest level of tension or discomfort. Scores will be recorded before and after progressive muscle relaxation (PMR) sessions, and changes in VAS scores over the 7-day intervention period will be summarized descriptively.

    Time frame: Baseline (Day 1) through Day 7 following enrollment.

  4. Participant Satisfaction with VR-Guided Progressive Muscle Relaxation Intervention Using a Post-Intervention Acceptability Survey

    Participant acceptability of the intervention will be assessed using a brief post-intervention acceptability survey administered at Day 7 (or discharge if earlier). Participants will rate overall satisfaction, usability, comfort, and willingness to use the VR-guided progressive muscle relaxation intervention again using 5-point Likert scale responses ranging from 1 to 5, where 1 indicates very dissatisfied and 5 indicates very satisfied. Higher scores indicate greater satisfaction and acceptability of the intervention. Responses will be summarized descriptively.

    Time frame: Day 7 following enrollment or hospital discharge if earlier.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Protocol and Study statistical plan will be shared. Informed consent will also be shared.

Supporting information: Study protocol, Informed consent form

Time frame: 11/01/2025 - 11/01/2026

Access criteria: Clinicians and researchers interested in this study will be able to access IPD. These will be uploaded to the clinical trials.gov website. They will be able to access protocol, informed consent sheet as well as statistical analysis portrayed on protocol.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Nov 2027, 10 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Aug 2026 → Jan 2027, primary completion Nov 2026 → Nov 2027 and completion May 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jun 16, 2026
StartEst.
Jan 2027was Aug 2026
Primary completionEst.
Nov 1, 2027was Nov 2026
CompletionEst.
May 1, 2028was May 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Jan 2027
Nov 12, 2026
Primary completion
Nov 1, 2026→Nov 1, 2027
Nov 12, 2026
Study completion
May 1, 2027→May 1, 2028
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Aug 2026→Jan 2027
    Primary completion Nov 1, 2026→Nov 1, 2027
    Study completion May 1, 2027→May 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07649512
Responsible party
Renee Yin Shen Miu (DO, University of Arizona) — Principal investigator
First posted
Jun 16, 2026
Start date
Jan 2027 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Renee Miu, DO
Contact
rmiu@arizona.edu
786-505-5779
Michele Chu-Pilli
Contact
chum@arizona.edu
520-626-1183

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion